Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of cholesterol-bound paclitaxel fat emulsion versus paclitaxel injection followed by epirubicin and cyclophosphamide for neoadjuvant treatment of HER2-negative breast cancer
CTR20242315Phase 2Completed
- Sponsor
- Institute of Medical Biotechnology, Chinese Academy of Medical Sciences
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WH002, paclitaxel in breast cancer, sponsored by Institute of Medical Biotechnology, Chinese Academy of Medical Sciences. Started Jun 2024; status: completed.
02
Drugs
WH002paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20242315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242315.